ESMO 2018

EORTC abstracts at ESMO 2018

Results from a number of EORTC trials will be presented at ESMO2018 Congress in Munich, please see below  the title and presenters of the presentations:

Oral Presentation

  • An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients (EORTC QLQ-BC23)- EORTC QLQ-BR45

Presentation Number: 193O

Tumour Group: Quality of Life

Speaker: Vesna Bjelic-Radisic (Germany)

Date: 20.10.2018 – Lecture Time: 11:00 – Location: Hall A2 – Room 18

 

Poster Discussion

  • A randomised phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC – the ETOP and EORTC SPLENDOUR trial.

Presentation Number 1385PD

Tumour Group: Lung

Poster Presenter: Solange Peters (Switzerland)

Date: 21.10.2018 – Lecture Time 17:15 – Location: ICM – Room 13

 

  • Health-related quality of life in randomized controlled trials: a systematic review of prognostic significance

Presentation Number: 1540PD

Tumour Group: Quality of Life

Speaker: Justyna Mierzynska (Belgium)

Date: 22.10.2018 – Lecture Time: 16:30 – Location: Hall B3 – Room 21

 

Poster Display Session

  • Treatment patterns in elderly patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC): results from an EORTC led survey

Poster Board Number: 1106P

Tumour Group: Head & Neck

Poster Presenter: Sjoukje Oosting (The Netherlands)

Date: 21.10.2018 – Lecture Time: 13:05 – 13:05 – Location: Hall A3 – Poster Area Networking Hub

 

  • Combined analysis of gene expression profiles in 2 preoperative trials with afatinib and cetuximab in head and neck squamous cell carcinoma

Poster Board Number: 1086P

Tumour Group: Head & Neck

Poster Presenter: Paolo Bossi (Italy)

Date: 21.10.2018 – Lecture Time: 13:05 – Location: Hall B3 – Poster Area

 

  • Health-related quality-of-life results for pembrolizumab versus placebo after complete resection of high-risk stage III melanoma from the EORTC 1325-MG/Keynote 054 trial: an international randomized double-blind phase 3 trial.

Poster Board Number: 1278P

Tumour Group: Quality of Life

Poster Presenter: Corneel Coens (Belgium)

Date: 21.10.2018 – Lecture Time: 13:05 – Location: Hall B3 – Poster Area

Back to news list